Literature DB >> 30078614

Functions of the CXC ligand family in the pancreatic tumor microenvironment.

Nien-Hung Lee1, Mehrdad Nikfarjam1, Hong He2.   

Abstract

Therapeutic resistance is the major contributor to the poor prognosis of and low survival from pancreatic cancer (PC). Cancer progression is a complex process reliant on interactions between the tumor and the tumor microenvironment (TME). Members of the CXCL family of chemokines are present in the pancreatic TME and seem to play a vital role in regulating PC progression. As pancreatic tumors interact with the TME and with PC stem cells (CSCs), determining the roles of specific members of the CXCL family is vital to the development of improved therapies. This review highlights the roles of selected CXCLs in the interactions between pancreatic tumor and its stroma, and in CSC phenotypes, which can be used to identify potential treatment targets.
Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CXC ligands; Cancer stem cells; Chemoresistance; Pancreatic cancer; Tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 30078614     DOI: 10.1016/j.pan.2018.07.011

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  11 in total

1.  CCL25 Signaling in the Tumor Microenvironment.

Authors:  Hina Mir; Shailesh Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway.

Authors:  Ying Ren; Yue Kai Gu; Zhen Li; Guang Zi Xu; Yang Meng Zhang; Min Xin Dong; Ying Wang; Xi Bing Zhou
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

3.  Identification and analysis of immune-related subtypes of hepatocellular carcinoma.

Authors:  Qimeng Wang; Jin Huang; Huihua Zhang; Huan Liu; Min Yu
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-24

4.  CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.

Authors:  Hui-Feng Gao; Chien-Shan Cheng; Jian Tang; Ye Li; Hao Chen; Zhi-Qiang Meng; Zhen Chen; Lian-Yu Chen
Journal:  Aging (Albany NY)       Date:  2020-01-08       Impact factor: 5.682

5.  Prognostic biomarkers and therapeutic targets in oral squamous cell carcinoma: a study based on cross-database analysis.

Authors:  Wanli Yang; Wei Zhou; Xinhui Zhao; Xiaoqian Wang; Lili Duan; Yiding Li; Liaoran Niu; Junfeng Chen; Yujie Zhang; Yu Han; Daiming Fan; Liu Hong
Journal:  Hereditas       Date:  2021-04-23       Impact factor: 3.271

6.  Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.

Authors:  Yanhua Jing; Fengjiao Wang; Ke Zhang; Zhen Chen
Journal:  BMC Med Genomics       Date:  2022-04-25       Impact factor: 3.622

7.  Senescent Human Pancreatic Stellate Cells Secrete CXCR2 Agonist CXCLs to Promote Proliferation and Migration of Human Pancreatic Cancer AsPC-1 and MIAPaCa-2 Cell Lines.

Authors:  Tetsuya Takikawa; Shin Hamada; Ryotaro Matsumoto; Yu Tanaka; Fumiya Kataoka; Akira Sasaki; Atsushi Masamune
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

8.  Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment.

Authors:  Weina Kong; Gang Zhao; Haixia Chen; Weina Wang; Xiaoqian Shang; Qiannan Sun; Fan Guo; Xiumin Ma
Journal:  Cancer Cell Int       Date:  2021-07-28       Impact factor: 5.722

9.  Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor.

Authors:  Iván A González; Liang-I Kang; Gregory A Williams; Jingxia Liu; David G DeNardo; William G Hawkins; Deyali Chatterjee
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.298

10.  Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs).

Authors:  Yecheng Li; Pingan Yao; Kui Zhao; Zhenyu Ye; Haobo Zhang; Jianping Cao; Shuyu Zhang; Chungen Xing
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.